Nanobio and Nanomedicine

Develops targeted molecular imaging agents and therapeutics designed to detect and treat cancer and cardiovascular disease.

Keystone Nano has an exclusive license to Penn State patented technology that allows the creation of stable, non-toxic, 5 to 50 nm-composite particles that they call Molecular Dots (MDs). These Molecular Dots can encapsulate drugs and/or fluorescent molecules.

Kylin has developed a patented RNA nanoparticle technology called 'pRNA' to exploit the enormous potential of RNA interference (RNAi) for treatment of many common diseases.